CoEnzyme Q10

Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. (read study)

Singh RB, Neki NS, Kartikey K, Pella D, Kumar A, Niaz MA, Thakur AS

Medical Hospital and Research Centre, Moradabad, India. icn@mickyonline.com

In a randomized, double-blind, controlled trial, the effects of oral treatment with coenzyme Q10 (CoQ10, 120 mg/day), a bioenergetic and antioxidant cytoprotective agent, were compared for 1 year, on the risk factors of atherosclerosis, in 73 (CoQ, group A) and 71 (B vitamin group B) patients after acute myocardial infarction (AMI). After 1 year, total cardiac events (24.6 vs. 45.0%, p < 0.02) including non-fatal infarction (13.7 vs. 25.3%, p < 0.05) and cardiac deaths were significantly lower in the intervention group compared to control group. The extent of cardiac disease, elevation in cardiac enzymes, left ventricular enlargement, previous coronary artery disease and elapsed time from symptom onset to infarction at entry to study showed no significant differences between the two groups. Plasma level of vitamin E (32.4 +/- 4.3 vs. 22.1 +/- 3.6 umol/L) and high density lipoprotein cholesterol (1.26 +/- 0.43 vs. 1.12 +/- 0.32 mmol/L) showed significant (p < 0.05) increase whereas thiobarbituric acid reactive substances, malondialdehyde (1.9 + 0.31 vs. 3.1 + 0.32 pmol/L) and diene conjugates showed significant reduction respectively in the CoQ group compared to control group. Approximately half of the patients in each group (n = 36 vs. 31) were receiving lovastatin (10 mg/day) and both groups had a significant reduction in total and low density lipoprotein cholesterol compared to baseline levels. It is possible that treatment with CoQ10 in patients with recent MI may be beneficial in patients with high risk of atherothrombosis, despite optimal lipid lowering therapy during a follow-up of 1 year. Adverse effect of treatments showed that fatigue (40.8 vs. 6.8%, p < 0.01) was more common in the control group than CoQ group.

Mol Cell Biochem., 2003 Apr;246(1-2):75-82

CoQ10 Gives Complete Protection Against Stroke

Since 1972, in studies of stroke in three animal models (dog, rat, gerbil), ubiquinone (coq10) was the only agent giving complete protection and this was over two times more often than the next best agent (naloxone) of the many tested to date.(http://faculty.washington.edu/ely/coenzq10abs.html)

CoQ10 benefits Cardiovascular Disease

CoQ10 levels in heart tissue decline disproportionately with age. CoQ10 pioneer Karl Folkers (1985), in agreement with earlier Japanese studies, found lower CoQ10 levels in patients with more severe heart disease and showed that CoQ10 supplements significantly raised blood and heart tissue levels of CoQ10 in these patients. http://faculty.washington.edu/ely/coenzq10.html)

CoQ10 Improves High Blood Pressure

At least six clinical trials have shown a blood pressure-lowering effect of CoQ10.

(http://content.intramedicine.com/dse/consumer/monoAll-style.asp?objD-100015&ctype-ds&mtyp-4)